Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
SEMAGLUTIDE
NOVO NORDISK CANADA INC
A10BJ06
SEMAGLUTIDE
6.8MG
SOLUTION
SEMAGLUTIDE 6.8MG
SUBCUTANEOUS
100
Prescription
Active ingredient group (AIG) number: 0159870008; AHFS:
APPROVED
2022-06-30
Wegovy™ (semaglutide injection) Product Monograph Page 1 of 60 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR WEGOVY ® semaglutide injection Solution for Subcutaneous Injection in a pre-filled pen Single-use pre-filled pen delivering doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg 0.25 mg/pen (0.25 mg/0.5 mL) 0.5 mg/pen (0.5 mg/0.5 mL) 1 mg/pen (1 mg/0.5 mL) 1.7 mg/pen (1.7 mg/0.75mL) 2.4 mg/pen (2.4 mg/0.75mL) and Multi-use pre-filled pen (FlexTouch ® ) delivering doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg 1 mg/pen (0.68 mg/mL) 2 mg/pen (1.34 mg/mL) 4 mg/pen (1.34 mg/mL) 6.8 mg/pen (2.27 mg/mL) 9.6 mg/pen (3.2 mg/mL) ATC code: A10BJ06 Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Novo Nordisk Canada Inc. 101-2476 Argentia Road Mississauga, Ontario L5N 6M1 Date of Initial Authorization: November 23, 2021 Date of Revision: June 29, 2023 Submission Control No: 266244 _ _ Wegovy ® (semaglutide injection) Product Monograph Page 2 of 60 RECENT MAJOR LABEL CHANGES 1 INDICATIONS TBD 4 DOSAGE AND ADMINISTRATION TBD 7 WARNINGS AND PRECAUTIONS TBD TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS.................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................. 4 1 INDICATIONS ...................................................................................................... 4 1.1 Pediatrics ..................................................................................................... 4 1.2 Geriatrics ..................................................................................................... 5 2 CONTRAINDICATIONS ...................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................. Baca dokumen lengkapnya